AcelRx Makes Headway With Second Pain Drug-Device Combo

With its lead drug candidate Zalviso in US FDA limbo, AcelRx Pharmaceuticals is focused on its other late-stage pain drug ARX-04, a health care professional-administered sublingual tablet that delivered fast relief of moderate-to-severe post-surgical pain for patients enrolled in a Phase III clinical trial.